After proving activity in patient with FRα-positive (IHC 2+ in ≥25% of tumor cells) platinum-resistant OC (ORR 26%),100 MIRV outcomes were evaluated according to FRα expression, demonstrating that high-FRα levels (IHC 2+ in ≥75% of tumor cells) were associated to better ORR.101. This evidence concerns the gene FOLR1 and neoplasm.